Changes in the use of various drug treatment in the Tsunami (−) and Tsunami (+) groups
Tsunami (−) | Tsunami (+) | p Value | |||||
Before | After | % Change 1 | Before | After | % Change 2 | ||
Hypoglycaemic agents | |||||||
Sulfonylureas | 15 | 11 | −26.7 | 11 | 5 | −54.6 | <0.01 |
Glinides | 18 | 16 | −11.1 | 9 | 2 | −77.8 | <0.01 |
α-Glucosidase inhibitors | 17 | 17 | 0 | 12 | 12 | 0 | NS |
Biguanides | 27 | 25 | −7.4 | 17 | 3 | −82.4 | <0.01 |
Pioglitazone | 19 | 17 | −10.5 | 9 | 1 | −88.9 | <0.01 |
DPP-4 inhibitors | 16 | 15 | −6.3 | 6 | 0 | −100.0 | <0.01 |
Insulin therapies | 13 | 13 | 0.0 | 13 | 4 | −69.2 | <0.01 |
GLP-1 analogues | 0 | 0 | 0.0 | 2 | 0 | −100.0 | – |
Antihypertensive agents | |||||||
RAS inhibitors | 20 | 7 | −65.0 | 7 | 0 | −100.0 | <0.01 |
CCBs | 17 | 15 | −11.8 | 15 | 7 | −53.3 | <0.01 |
Diuretics | 13 | 6 | −53.9 | 10 | 1 | −90.0 | <0.01 |
Others | 7 | 3 | −57.1 | 8 | 0 | −100.0 | <0.01 |
p, % Change 1 versus % change 2.
CCB, calcium channel blocker; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like polypeptide-1; RAS, renin–angiotensin system.